Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Lucia Nappi

Showing results (31-40 of 65) with videos related to

Pageof 7
Sort By:
Scientific Reports|April 28, 2025
Author Correction: Circulating microRNA-155-3p levels predicts response to first line immunotherapy in patients with metastatic renal cell carcinomaMaryam Soleimani, Marisa Thi, Sajjad Janfaza, et al.
Scientific Reports|April 13, 2024
Circulating microRNA-155-3p levels predicts response to first line immunotherapy in patients with metastatic renal cell carcinomaMaryam Soleimani, Marisa Thi, Sajjad Janfaza, et al.
Plos One|May 9, 2025
Matching plasma and tissue miRNA expression analysis to detect viable ovarian germ cell tumorsArkhjamil Angeles, Nastaran Khazamipour, Gurdial Dhillon, et al.
Proteomics|January 3, 2013
Increased anaerobic metabolism is a distinctive signature in a colorectal cancer cellular model of resistance to antiepidermal growth factor receptor antibodyFrancesca Monteleone, Roberta Rosa, Monica Vitale, et al.
EMBO Molecular Medicine|May 21, 2016
Clusterin knockdown sensitizes prostate cancer cells to taxane by modulating mitosisNader Al Nakouzi, Chris Kedong Wang, Eliana Beraldi, et al.
Frontiers in Oncology|September 30, 2022
Comprehensive immune profiling of patients with advanced urothelial or renal cell carcinoma receiving immune checkpoint blockadeJean-Michel Lavoie, Priya Baichoo, Elizabeth Chavez, et al.
Anti-Cancer Drugs|May 23, 2013
Tumor-to-tumor metastasis: breast cancer metastatic to thymic epithelial tumorRoberto Moretto, Chiara A Cella, Lucia Raimondo, et al.
The Prostate|November 29, 2022
Exploring new frontiers in prostate cancer research: Report from the 2022 Coffey-Holden prostate cancer academy meetingAndrea K Miyahira, Jessica E Hawley, Remi Adelaiye-Ogala, et al.
European Journal of Cancer (Oxford, England : 1990)|June 15, 2021
Effectiveness of first-line abiraterone versus enzalutamide among patients ≥80 years of age with metastatic castration-resistant prostate cancer: A retrospective propensity score-weighted comparative cohort studyMaryam Soleimani, Kevin Zou, Katherine Sunderland, et al.
The Oncologist|September 27, 2022
TP53 Alterations Are Associated With Poor Survival in Patients With Primary Mediastinal Nonseminoma Germ Cell TumorsJack V W Bacon, Patrizia Giannatempo, Giovanna Cataldo, et al.
Pageof 7

Showing results (31-40 of 65) with videos related to

Sort By:
Pageof 7
Scientific Reports|April 28, 2025
Author Correction: Circulating microRNA-155-3p levels predicts response to first line immunotherapy in patients with metastatic renal cell carcinomaMaryam Soleimani, Marisa Thi, Sajjad Janfaza, et al.
Scientific Reports|April 13, 2024
Circulating microRNA-155-3p levels predicts response to first line immunotherapy in patients with metastatic renal cell carcinomaMaryam Soleimani, Marisa Thi, Sajjad Janfaza, et al.
Plos One|May 9, 2025
Matching plasma and tissue miRNA expression analysis to detect viable ovarian germ cell tumorsArkhjamil Angeles, Nastaran Khazamipour, Gurdial Dhillon, et al.
Proteomics|January 3, 2013
Increased anaerobic metabolism is a distinctive signature in a colorectal cancer cellular model of resistance to antiepidermal growth factor receptor antibodyFrancesca Monteleone, Roberta Rosa, Monica Vitale, et al.
EMBO Molecular Medicine|May 21, 2016
Clusterin knockdown sensitizes prostate cancer cells to taxane by modulating mitosisNader Al Nakouzi, Chris Kedong Wang, Eliana Beraldi, et al.
Frontiers in Oncology|September 30, 2022
Comprehensive immune profiling of patients with advanced urothelial or renal cell carcinoma receiving immune checkpoint blockadeJean-Michel Lavoie, Priya Baichoo, Elizabeth Chavez, et al.
Anti-Cancer Drugs|May 23, 2013
Tumor-to-tumor metastasis: breast cancer metastatic to thymic epithelial tumorRoberto Moretto, Chiara A Cella, Lucia Raimondo, et al.
The Prostate|November 29, 2022
Exploring new frontiers in prostate cancer research: Report from the 2022 Coffey-Holden prostate cancer academy meetingAndrea K Miyahira, Jessica E Hawley, Remi Adelaiye-Ogala, et al.
European Journal of Cancer (Oxford, England : 1990)|June 15, 2021
Effectiveness of first-line abiraterone versus enzalutamide among patients ≥80 years of age with metastatic castration-resistant prostate cancer: A retrospective propensity score-weighted comparative cohort studyMaryam Soleimani, Kevin Zou, Katherine Sunderland, et al.
The Oncologist|September 27, 2022
TP53 Alterations Are Associated With Poor Survival in Patients With Primary Mediastinal Nonseminoma Germ Cell TumorsJack V W Bacon, Patrizia Giannatempo, Giovanna Cataldo, et al.
Pageof 7